SHIMIZU Tomokazu    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Associate Professor
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Outcomes of kidney transplantation in recipients with SARS-cov-2 infection: a 282-case single-center experience in Japan.
Journal	Formal name：Clinical and experimental nephrology Abbreviation：Clin Exp Nephrol ISSN code：13421751/14377799
Domestic / Foregin	Foregin
Volume, Issue, Page	29(2),pp.182-191
Author and coauthor	Sekido Eri, Unagami Kohei, Omoto Kazuya, Arimura Ken, Moriyama Ikumi, Banno Taro, Saito Ayaka, Oki Rikako, Okada Daigo, Yagisawa Takafumi, Kanzawa Taichi, Kitajima Kumiko, Hirai Toshihito, Shimizu Tomokazu, Yamanaga Shigeyoshi, Egawa Hiroto, Inui Masashi, Hoshino Junichi, Ishida Hideki, Takagi Toshio
Publication date	2025/02
Summary	Abstract Background: The coronavirus disease 2019, caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has become a global epidemic. There are concerns regarding the severity of SARS-CoV-2 infections in kidney transplant (KTx) recipients. However, there is limited data on how the epidemic has affected the treatment and prognosis of these patients. Therefore, we aimed to report the changes in the treatment and outcomes of KTx recipients infected with SARS-CoV-2 during each wave at our institution. Methods: A total of 282 KTx recipients who were infected with SARS-CoV-2 during the study period were followed up at Tokyo Women's Medical University between March 2020 and August 2022. We investigated the outcomes and treatments of infected KTx recipients. Results: Nineteen (6.7%) patients showed severe outcomes, including eight SARS-CoV-2 infection-related deaths. Risk factors associated with severe outcomes included underlying conditions, such as diabetes mellitus, heart disease, and liver disease (odds ratios, 2.09, 2.88, and 5.52, respectively). Treatment strategies changed throughout the epidemic in response to changes in the SARS-CoV-2 variants. Antiviral drugs were gradually administered as soon as they were approved for use. Conclusions: Treatment strategies for KTx recipients were gradually established over the course of the epidemic. Although the proportion of infected KTx recipients decreased compared to that of the general population throughout the epidemic, many patients still followed a severe course.
DOI	10.1007/s10157-024-02560-0
PMID	39361181